Citigroup’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-1,404,192
| Closed | -$30.5M | – | 7646 |
|
|
2017
Q2 | $30.5M | Buy |
1,404,192
+1,384,255
| +6,943% | +$25.1M | 0.03% | 564 |
|
|
2017
Q1 | $279K | Sell |
19,937
-19,162
| -49% | -$314K | ﹤0.01% | 4372 |
|
|
2016
Q4 | $733K | Buy |
39,099
+9,314
| +31% | +$158K | ﹤0.01% | 3999 |
|
|
2016
Q3 | $492K | Buy |
29,785
+13,166
| +79% | +$195K | ﹤0.01% | 3905 |
|
|
2016
Q2 | $223K | Sell |
16,619
-1,000
| -6% | -$14.6K | ﹤0.01% | 4397 |
|
|
2016
Q1 | $270K | Buy |
17,619
+17,600
| +92,632% | +$276K | ﹤0.01% | 4802 |
|
|
2015
Q4 | $0 | Buy |
19
+15
| +375% | +$285 | ﹤0.01% | 8100 |
|
|
2015
Q3 | $0 | Sell |
4
-2,640
| -100% | -$53.8K | ﹤0.01% | 8045 |
|
|
2015
Q2 | $54K | Buy |
2,644
+2,081
| +370% | +$40.2K | ﹤0.01% | 5484 |
|
|
2015
Q1 | $10K | Sell |
563
-11,925
| -95% | -$203K | ﹤0.01% | 6481 |
|
|
2014
Q4 | $204K | Buy |
12,488
+11,459
| +1,114% | +$210K | ﹤0.01% | 4674 |
|
|
2014
Q3 | $22K | Buy |
1,029
+750
| +269% | +$15.4K | ﹤0.01% | 5863 |
|
|
2014
Q2 | $6K | Sell |
279
-10,077
| -97% | -$171K | ﹤0.01% | 6415 |
|
|
2014
Q1 | $193K | Sell |
10,356
-5,914
| -36% | -$81.4K | ﹤0.01% | 4365 |
|
|
2013
Q4 | $164K | Buy |
16,270
+3,869
| +31% | +$46.8K | ﹤0.01% | 4835 |
|
|
2013
Q3 | $160K | Buy |
12,401
+162
| +1% | +$1.99K | ﹤0.01% | 4357 |
|
|
2013
Q2 | $145K | Buy |
+12,239
| New | +$133K | ﹤0.01% | 4539 |
|
Other funds holding AMRI
Citigroup's AMRI Position: Q3 2017 in Review
Citigroup sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 1,404,192 shares — an estimated $30.5M sold.
Citigroup first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $30.5M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Citigroup reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Citigroup sold 1,404,192 Albany Molecular Research Inc shares in Q3 2017, an estimated $30.5M.
- Citigroup first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Citigroup's Albany Molecular Research Inc position peaked at $30.5M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Citigroup's 13F filing for Q3 2017, filed 13 Nov 2017.